VIRAGEN <VRGN> STARTS HUMAN TRIALS
Viragen Inc said it is sponsoring
clinical studies of Human Leukocyte Interferon, Alpha, in the
treatment of renal cell carcinoma and bladder cell carcinoma.
    The Food and Drug Administration approved human trials 
will be conducted on at least 30 patients, male and female for
each cancer type.
 Reuter
